News
TYRA
17.94
-2.23%
-0.41
BRIEF-Tyra Biosciences Announces Appointments Of Susan Moran, M.D., M.S.C.E. And S. Michael Rothenberg, M.D., Ph.D. To Its Board Of Directors
Tyra Biosciences Announces Appointments Of Susan Moran, M.D., M.S.C.E. And S. Michael Rothenberg, Ph.D. To Its Board Of Directors. The company says Moran will join the board of directors.
Reuters · 5h ago
TYRA BIOSCIENCES INC: BOARD APPROVED AN INCREASE IN NUMBER OF AUTHORIZED DIRECTORS FROM NINE TO TEN
Reuters · 5h ago
Tyra Bioscience Expands Board with Two New Appointments
TipRanks · 6h ago
Press Release: Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors
Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.E. And S. Michael Rothenberg, Ph.D. To its Board of Directors. The company is focused on developing next-generation precision medicines in Fibroblast Growth Factor Receptor biology. Dr. Moran led the development and approval of infigratinib.
Dow Jones · 6h ago
Weekly Report: what happened at TYRA last week (0429-0503)?
Weekly Report · 1d ago
Weekly Report: what happened at TYRA last week (0422-0426)?
Weekly Report · 04/29 09:04
Weekly Report: what happened at TYRA last week (0415-0419)?
Weekly Report · 04/22 09:04
Weekly Report: what happened at TYRA last week (0408-0412)?
Weekly Report · 04/15 09:03
Weekly Report: what happened at TYRA last week (0401-0405)?
Weekly Report · 04/08 09:03
Weekly Report: what happened at TYRA last week (0325-0329)?
Weekly Report · 04/01 09:04
Tyra Bioscience Poised for Growth: Buy Rating Affirmed Amid Promising Clinical Trials and Strategic Drug Development
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on Tyra Bioscience stock. The company's lead drug candidate, TYRA-300, has the potential to be a best-in-class treatment for cancer. The stock has been given a Buy rating on March 21.
TipRanks · 03/26 10:26
Weekly Report: what happened at TYRA last week (0318-0322)?
Weekly Report · 03/25 09:03
Tyra Biosciences Price Target Maintained With a $28.00/Share by Wedbush
Dow Jones · 03/21 12:57
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)
Analysts have new ratings on Vera Therapeutics, Tyra Bioscience and Tenaya Therapeutic. The Healthcare sector has been in the spotlight recently. Wedbush maintained a Hold rating on VeraTherapeutics today and set a price target of $34.00. Tenaya has an analyst consensus of Strong Buy.
TipRanks · 03/21 12:50
Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $28 Price Target
Benzinga · 03/21 12:47
Tyra Bioscience Gains Pediatric Disease Designation for Achondroplasia Drug Amid FDA Voucher Uncertainty
TipRanks · 03/21 06:02
Analysts Offer Insights on Healthcare Companies: Nyxoah (NYXH), Tyra Bioscience (TYRA) and Crinetics Pharmaceuticals (CRNX)
3 analysts maintain Buy ratings on Nyxoah (NYXH), Tyra Bioscience and Crinetics Pharmaceuticals. The Healthcare sector has 3 of the top 10 most bullish stocks in the world. The 3 stocks have a combined market value of more than $1.5 billion.
TipRanks · 03/20 12:00
Tyra Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Tyra Biosciences Inc reports results for the quarter ended in December. Reported revenue was zero; analysts expected zero. The company reported a quarterly loss of $22.83 million. Shares had risen by 16.2% this quarter. Wall Street's median 12-month price target for the company is $25.00.
Reuters · 03/20 12:00
Tyra Biosciences Price Target Raised to $23.00/Share From $19.00 by HC Wainwright & Co.
Dow Jones · 03/20 10:53
HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Raises Price Target to $23
Benzinga · 03/20 10:42
More
Webull provides a variety of real-time TYRA stock news. You can receive the latest news about Tyra Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.